Prospective Grant of Exclusive Patent License: Use of Pharmaceutical and Biological Compositions Comprising Gram-Negative Bacteria for the Topical Treatment of Dermatological Diseases and Dermatological Conditions, 47759 [2017-22148]
Download as PDF
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: David B. Winter, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204,
MSC 7812, Bethesda, MD 20892, 301–435–
1152, dwinter@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 6, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–22140 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Use of Pharmaceutical and
Biological Compositions Comprising
Gram-Negative Bacteria for the Topical
Treatment of Dermatological Diseases
and Dermatological Conditions
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to
Forte Biosciences, Inc. located in San
Diego, California.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before October 30,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: David
Yang, Technology Transfer and
Patenting Specialist, Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, National Institutes
of Health, 5601 Fishers Lane, Suite 6D,
Rockville, MD 20852–9804; Email:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
yangp3@nih.gov; Telephone: (240) 627–
3413; Facsimile: (240) 627–3117.
SUPPLEMENTARY INFORMATION:
Intellectual Property
U.S. Provisional Application 62/
324,762, filed April 19, 2016, and PCT
Patent Application PCT/US2017/
028133, filed April 17, 2017, both
entitled ‘‘Use of Gram Negative Species
to Treat Atopic Dermatitis’’ [HHS Ref.
E–099–2016/0], and U.S. and foreign
patent applications claiming priority to
the aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the
following field of use: ‘‘Use of
pharmaceutical and biological
compositions comprising Gram-negative
bacteria for the topical treatment of
dermatological diseases and
dermatological conditions’’.
Atopic dermatitis (AD) is a common,
recurrent, chronic inflammatory skin
disease that is a cause of considerable
economic and social burden. It is one of
the most prevalent skin disorders,
affecting ∼25% of children in developed
and developing countries and is
expected to continue to escalate. This
increased rate of incidence has changed
the focus of research on AD toward
epidemiology, prevention, and
treatment.
The subject technology describes
pharmaceutical and biological
compositions comprising Gram-negative
bacteria that can be developed into a
topical treatment for atopic dermatitis
(AD), as well as methods and kits using
these compositions.
NIAID scientists have recently
identified probiotic strains of
Roseomonas mucosa bacteria that were
shown to be beneficial in a pre-clinical
mouse model of AD. With this
promising data, NIAID launched a phase
I/II clinical trial in March 2017 (link;
https://clinicaltrials.gov/ct2/show/
NCT03018275) and preliminary results
from this ongoing study show that the
technology may be highly effective at
treating and reducing the symptoms of
atopic dermatitis. If successfully
developed, this invention would be the
first live biotherapeutic product
approved by the FDA for the treatment
of AD.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
47759
Institute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 4, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–22148 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Senior Executive Service Performance
Review Board
Office of the Secretary,
Department of Homeland Security
(DHS).
ACTION: Notice.
AGENCY:
This notice announces the
appointment of the members of the
Senior Executive Service (SES)
Performance Review Board (PRB) for
DHS. The purpose of the PRB is to view
and make recommendations concerning
proposed performance appraisals,
ratings, bonuses, pay adjustments, and
other appropriate personnel actions for
incumbents of SES, Senior Level and
Senior Professional positions of the
Department.
DATES: The PRB members’ terms begin
October 13, 2017.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Haefeli, Office of the Chief
Human Capital Officer,
Elizabeth.Haefeli@hq.dhs.gov, or by
telephone (202) 357–8164.
SUPPLEMENTARY INFORMATION: Each
Federal agency is required to establish
one or more performance review boards
to make recommendations, as necessary,
in regard to the performance of senior
executives within the agency. 5 U.S.C.
4314(c). This notice announces the
appointment of the members of the PRB
for DHS. The purpose of the PRB is to
review and make recommendations
concerning proposed performance
SUMMARY:
E:\FR\FM\13OCN1.SGM
13OCN1
Agencies
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Page 47759]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22148]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Use of
Pharmaceutical and Biological Compositions Comprising Gram-Negative
Bacteria for the Topical Treatment of Dermatological Diseases and
Dermatological Conditions
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive
Commercialization Patent License to practice the inventions embodied in
the Patents and Patent Applications listed in the Summary Information
section of this notice to Forte Biosciences, Inc. located in San Diego,
California.
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Allergy and Infectious
Diseases' Technology Transfer and Intellectual Property Office on or
before October 30, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Commercialization
Patent License should be directed to: David Yang, Technology Transfer
and Patenting Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Suite 6D, Rockville, MD 20852-
9804; Email: yangp3@nih.gov; Telephone: (240) 627-3413; Facsimile:
(240) 627-3117.
SUPPLEMENTARY INFORMATION:
Intellectual Property
U.S. Provisional Application 62/324,762, filed April 19, 2016, and
PCT Patent Application PCT/US2017/028133, filed April 17, 2017, both
entitled ``Use of Gram Negative Species to Treat Atopic Dermatitis''
[HHS Ref. E-099-2016/0], and U.S. and foreign patent applications
claiming priority to the aforementioned applications.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the following field of use: ``Use of
pharmaceutical and biological compositions comprising Gram-negative
bacteria for the topical treatment of dermatological diseases and
dermatological conditions''.
Atopic dermatitis (AD) is a common, recurrent, chronic inflammatory
skin disease that is a cause of considerable economic and social
burden. It is one of the most prevalent skin disorders, affecting ~25%
of children in developed and developing countries and is expected to
continue to escalate. This increased rate of incidence has changed the
focus of research on AD toward epidemiology, prevention, and treatment.
The subject technology describes pharmaceutical and biological
compositions comprising Gram-negative bacteria that can be developed
into a topical treatment for atopic dermatitis (AD), as well as methods
and kits using these compositions.
NIAID scientists have recently identified probiotic strains of
Roseomonas mucosa bacteria that were shown to be beneficial in a pre-
clinical mouse model of AD. With this promising data, NIAID launched a
phase I/II clinical trial in March 2017 (link; https://clinicaltrials.gov/ct2/show/NCT03018275) and preliminary results from
this ongoing study show that the technology may be highly effective at
treating and reducing the symptoms of atopic dermatitis. If
successfully developed, this invention would be the first live
biotherapeutic product approved by the FDA for the treatment of AD.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Institute of Allergy and Infectious Diseases receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Commercialization Patent
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: October 4, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-22148 Filed 10-12-17; 8:45 am]
BILLING CODE 4140-01-P